Circulating MiR-133a as a biomarker predicts cardiac hypertrophy in chronic hemodialysis patients.

Abstract

BACKGROUND:

MicroRNAs (miRNAs) are small ribonucleotides regulating gene expression. MicroRNAs are present in the blood in a remarkably stable form and have emerged as potential diagnostic markers in patients with cardiovascular disease. Our study aimed to assess circulating miR-133a levels in MHD patients and the relation of miR-133a to cardiac hypertrophy.

METHODS:

We profiled miRNAs using RNA isolated from the plasma of participants. The results were validated in 64 MHD patients and 18 healthy controls.

RESULTS:

Levels of plasma miR-133a decreased in MHD patients with LVH compared with those in healthy controls. Plasma miR-133a concentrations were negatively correlated with LVMI and IVS. After single hemodialytic treatment, plasma miR-133a levels remained unchanged. Cardiac Troponin I and T were not associated with LVMI and IVS.

CONCLUSIONS:

Our observations supplied the possibility that circulating miR-133a could be a surrogate biomarker of cardiac hypertrophy in MHD patients.

• Authors: Ping Wen, Dan Song, Hong Ye, Xiaochun Wu, Lei Jiang, Bing Tang, Yang Zhou, Li Fang, Hongdi Cao, Weichun He, Yafang Yang, Chunsun Dai, Junwei Yang
• Journal: PloS one (PLoS One) Vol. 9 Issue 10 Pg. e103079 ( 2014) ISSN: 1932-6203 [Electronic] United States
• PMID: 25313674 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Biomarkers
• MIRN133 microRNA, human
• MicroRNAs
• Troponin I
• Troponin T

Topics

• Adult
• Aged
• Aged, 80 and over
• Biomarkers (blood)
• Cardiomegaly (complications, diagnosis, genetics)
• Female
• Heart Ventricles (diagnostic imaging)
• Humans
• Kidney Failure, Chronic (complications, diagnosis)
• Logistic Models
• Magnetic Resonance Imaging
• Male
• MicroRNAs (blood)
• Middle Aged
• Renal Dialysis
• Troponin I (metabolism)
• Troponin T (metabolism)
• Ultrasonography